If you have been tracking the medical technology sector, the story of asxc stock (Asensus Surgical, Inc.) is one of the most fascinating narratives of innovation, financial struggle, and eventual corporate consolidation. For years, retail investors closely watched Asensus Surgical as it attempted to challenge industry behemoths like Intuitive Surgical in the rapidly expanding robotic surgery market. However, if you look at your stock tracking app today, you will notice that the ASXC ticker is no longer active, and its price has remained frozen at $0.35 since late 2024.
So, what actually happened to asxc stock, is it still trading, and what happened to the shares held by retail investors? In this comprehensive guide, we provide a complete post-acquisition update. We will explore the mechanics of the KARL STORZ buyout, explain how old shares were processed, dive into the groundbreaking technology that made the company a prime acquisition target, and look at the company’s recent private development milestones.
What Happened to ASXC Stock? The KARL STORZ Acquisition
On August 22, 2024, Asensus Surgical officially announced the completion of its merger with the KARL STORZ Group. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc. (a wholly owned direct subsidiary of German medical technology giant KARL STORZ SE & Co. KG) acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash.
The transaction, valued at approximately $93.45 million, was completed following approval by Asensus Surgical stockholders at a special meeting. Upon the closing of the transaction, Asensus Surgical became a wholly owned private subsidiary of KARL STORZ. As a result, the common stock of Asensus Surgical ceased trading on the NYSE American Exchange, and the ASXC ticker was officially delisted.
For Asensus, the merger served as a critical lifesaver. Prior to the acquisition, the company was burning through cash at an unsustainable rate. In its Q1 2024 financial results, the company reported a massive net loss of $22.5 million on just $1.1 million in revenue. With only $8.0 million in cash and cash equivalents remaining on its balance sheet, the company openly stated in SEC filings that it faced imminent bankruptcy if stockholders did not approve the merger. The buyout at $0.35 per share represented a premium of over 50% compared to the stock's trading price prior to the initial acquisition proposal, providing a structured exit for shareholders while securing the survival of the company’s digital surgery technology.
The History of Asensus Surgical: From TransEnterix to ASXC
To understand the rise and fall of ASXC stock, it is helpful to look back at the company’s origins. Founded in 2006 as TransEnterix, Inc., the company set out to revolutionize minimally invasive surgery (MIS). Trading under the ticker symbol TRXC, the company initially focused on developing the Spider Surgical System and later the SurgiBot System, a single-port robot.
However, in 2015, the company made a strategic pivot by acquiring the assets of SOFAR S.p.A., an Italian healthcare company. This acquisition brought with it the TELELAP ALF-X robotic system, which TransEnterix rebranded as the Senhance Surgical System. When the FDA rejected the SurgiBot system in 2016, the company put all of its resources behind Senhance, eventually securing FDA 510(k) clearance for the platform in late 2017.
In early 2021, TransEnterix rebranded itself as Asensus Surgical, Inc. and changed its stock ticker to ASXC. The rebranding was intended to signal a transition from traditional hardware-focused robotic surgery to "Performance-Guided Surgery." This new paradigm integrated artificial intelligence, machine learning, and computer vision to assist surgeons in the operating room.
Despite the advanced capabilities of the Senhance System, Asensus struggled with clinical adoption. Selling multi-million-dollar robotic systems to cash-strapped hospitals is notoriously difficult, particularly when competing against the established market dominance of Intuitive Surgical's da Vinci platform. As marketing and R&D costs mounted, the company's financial health deteriorated, culminating in the 2024 acquisition.
What Happened to Your Shares? How the Cash Merger Works
If you owned shares of asxc stock prior to the merger, you might be wondering where your shares went and how you can claim your money. Because this transaction was a "cash merger" (meaning KARL STORZ bought the company entirely with cash rather than stock), the transition was handled automatically through brokerage systems:
- Automatic Liquidation: Brokerage firms (such as Robinhood, Webull, Fidelity, Charles Schwab, and E*TRADE) automatically processed the corporate action. Your ASXC shares were removed from your account, and you were credited with $0.35 in cash for every share you owned.
- Physical Stock Certificates: If you held physical stock certificates (which is rare for modern retail traders), you should have received a "Letter of Transmittal" containing instructions from the paying agent (typically Computershare). You must surrender your physical certificates to the paying agent to receive your cash payout.
- Tax Treatment: For tax purposes, the cash merger is treated as a sale of your stock. If your average purchase price was higher than $0.35 per share, you realized a capital loss. If your average cost basis was lower than $0.35, you realized a capital gain. Your broker will reflect this transaction on your 1099-B tax form.
- No Rollover Equity: Because KARL STORZ is a private, family-owned company, there was no option to exchange your ASXC shares for shares of the parent company. Your equity position was completely cashed out.
Why KARL STORZ Bought Asensus Surgical: Tech and Strategy
While public market investors struggled with the volatility of ASXC stock, KARL STORZ recognized the immense value in the company’s underlying intellectual property, clinical data, and engineering talent.
Founded in 1945 in Tuttlingen, Germany, KARL STORZ is a global powerhouse in endoscopy, visualization systems, and integrated operating room solutions. Historically, KARL STORZ viewed the surgical market through an "imaging lens" rather than a robotic one. However, the rapid evolution of surgical technology made it clear that digital and robotic solutions are the future of healthcare. By acquiring Asensus, KARL STORZ immediately added a robust robotic and digital surgery portfolio to its offerings.
Three primary technological assets drove KARL STORZ's decision to acquire Asensus:
1. The Intelligent Surgical Unit (ISU)
The Intelligent Surgical Unit (ISU) is widely regarded as Asensus's crown jewel. It is a real-time augmented intelligence system that uses advanced computer vision and machine learning. During laparoscopy, the ISU acts as a digital co-pilot. It automatically tracks the surgeon's eye movements to position the robotic camera, eliminating the need for an assistant to manually adjust the scope. It also provides virtual digital markers, distance measurements, and automated surgical field tracking directly on the console display.
2. The Senhance Surgical System
As a multi-port robotic platform, the Senhance System pioneered several critical features that set it apart from its competitors. It was the first platform to offer haptic feedback, allowing surgeons to actually feel the resistance of tissues through the robotic controls. It also featured an open console architecture, allowing surgeons to maintain a natural line of sight, and utilized reusable 5mm instruments, which significantly reduced the per-procedure cost for hospitals.
3. The Next-Generation LUNA Surgical System
At the time of the acquisition, Asensus was actively developing its next-generation platform, the LUNA Surgical System. Designed based on feedback from over 10,000 digital laparoscopic procedures performed with Senhance, LUNA was engineered to be a highly versatile, modular platform. It features advanced wristed instruments, natural hand-movement controls, and a compact footprint that can be easily integrated into standard operating rooms. KARL STORZ acquired Asensus specifically to fund and accelerate the development of LUNA, combining Asensus's robotics experience with its own state-of-the-art 3D and 4K imaging technology.
Where Are They Now? Asensus Surgical’s Private Milestones (2025/2026)
Although public updates on asxc stock news have stopped, the underlying business is incredibly active as a private entity. Free from the constant pressure of quarterly earnings calls and the threat of public bankruptcy, the Asensus team has been able to focus entirely on R&D under the KARL STORZ umbrella.
Since going private, the company has reached several major milestones:
Strategic Partnership with GlobalLogic
In October 2025, Asensus Surgical (now officially operating as "Part of KARL STORZ") announced a strategic, long-term engineering partnership with GlobalLogic, a Hitachi Group company. This collaboration is designed to leverage GlobalLogic’s global engineering scale to accelerate the development of the LUNA Surgical System and enhance the company's broader digital surgery portfolio using advanced AI and computer vision.
Establishing the Kraków V&V Lab
As part of the GlobalLogic partnership, a new dedicated development lab was established in Kraków, Poland. This world-class facility specializes in Verification and Validation (V&V) for complex medical devices. By replicating the exact Asensus Surgical engineering environment, the lab enables rapid, automated testing, ensuring that the software and robotics systems comply with rigorous global safety and regulatory standards.
AI Integration in R&D
Under the leadership of Dustin Vaughan, Vice President of R&D for Robotics, Asensus has heavily integrated artificial intelligence and generative model testing into its product pipeline. The company is actively combining the ISU’s augmented intelligence capabilities with KARL STORZ's legacy IMAGE1 S™ surgical video systems. This integration aims to deliver advanced real-time intraoperative data analysis, bringing Performance-Guided Surgery directly to operating rooms around the world.
Alternative Surgical Robotics Stocks to Watch
If the story of Asensus Surgical has left you wanting to invest in the medical robotics sector, you will need to look elsewhere, as asxc stock is no longer tradeable. Fortunately, several public companies offer excellent exposure to this high-growth medical technology market:
- Intuitive Surgical (NASDAQ: ISRG): The undisputed king of robotic surgery. Intuitive's da Vinci system is installed in thousands of hospitals worldwide, and the company's razor-and-blade business model generates highly predictable recurring revenue from instruments and accessories. Intuitive recently launched its da Vinci 5 platform, which is expected to drive a massive multi-year upgrade cycle.
- Medtronic (NYSE: MDT): For investors looking for a diversified, blue-chip healthcare stock, Medtronic is a compelling option. The company is actively scaling its Hugo RAS (Robotic-Assisted Surgery) system, competing directly with Intuitive in soft-tissue procedures.
- Johnson & Johnson (NYSE: JNJ): J&J is a healthcare colossus with massive capital reserves. The company is developing its Ottava robotic system, aiming to integrate it with its market-leading Ethicon surgical instruments. J&J offers significant long-term stability alongside its robotics growth potential.
- Stryker Corporation (NYSE: SYK): If you are interested in orthopedics, Stryker is the market leader. Its Mako system is the gold standard for robotic-assisted joint replacements (hips and knees), and the company continues to see strong placement numbers and procedure volume growth globally.
Frequently Asked Questions (ASXC Stock FAQ)
Is ASXC stock still active or trading?
No. ASXC stock was officially delisted from the NYSE American Exchange on August 22, 2024, following its acquisition by KARL STORZ. It is no longer an active publicly traded stock, and you cannot buy or sell shares on any public market.
What was the final buyout price for Asensus Surgical shares?
KARL STORZ acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. The deal valued the transaction at approximately $93.45 million.
What happened to my ASXC shares on Robinhood/Webull?
Your broker automatically liquidated your shares of ASXC and credited your account with $0.35 in cash per share. If you did not see this happen, check your account history for a "merger," "liquidation," or "cash in lieu" transaction dated late August 2024.
Can I buy stock in KARL STORZ?
No. KARL STORZ is a privately-held, family-owned company headquartered in Tuttlingen, Germany. There are currently no public shares available, and the company has expressed no intention to go public.
What is the status of the LUNA Surgical System in 2026?
Under KARL STORZ's ownership, the development of the LUNA system is highly active. In late 2025, Asensus partnered with GlobalLogic to establish a dedicated testing lab in Poland to accelerate software verification and prepare the LUNA platform for clinical trials and regulatory submissions.
Conclusion
The delisting of asxc stock marked the end of an era for retail investors who spent years following the company's journey on public exchanges. While Asensus Surgical struggled to survive as an independent, publicly traded micro-cap company, its acquisition by KARL STORZ has secured a bright future for its cutting-edge technology. Under private ownership, the development of the LUNA Surgical System and the Intelligent Surgical Unit has accelerated, fueled by the capital and distribution network of a global medical device giant. Although you can no longer invest in ASXC directly, the technology pioneered by Asensus will undoubtedly continue to shape the future of robotic and digital surgery for years to come.
